Posters

    Identification of the transcriptional gene network in 2D and 3D human bronchial epithelial cell culture systems

    Belcastro, V.; Mathis, C.; Poussin, C.; Weisensee, D.; Hoeng, J.
    Conference date
    Jul 17, 2011
    Conference name

    19th Annual International Conference on Intelligent Systems for Molecular Biology
    Link to more information
    Topic
    Summary

    Background: Microarray gene expression technology has become standard practice in systems biology to analyze transcriptomic changes at the cell, tissue, and organism level, enabling the reverse-engineering of condition-specific gene networks. Purpose: To better understand how transcriptional gene networks of biologically close cellular systems, differ, two specific networks were reverse-engineered from 2D and 3D human normal bronchial epithelial cell cultures. Methods: 100 gene expression profiles for both normal human bronchial epithelial (NHBE) cells and organotypically differentiated bronchial cells (AIR100 culture) were collected under normal culture conditions. Gene networks were reconstructed by correlating gene expression profiles at a false discovery rate (FDR, T-statistic and Benjamini-Hochberg correction). 

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.